QV Investors Inc. Trims Stake in Johnson & Johnson (NYSE:JNJ)

QV Investors Inc. reduced its position in Johnson & Johnson (NYSE:JNJ) by 1.8% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 97,110 shares of the company’s stock after selling 1,770 shares during the period. Johnson & Johnson accounts for about 1.3% of QV Investors Inc.’s portfolio, making the stock its 26th largest position. QV Investors Inc.’s holdings in Johnson & Johnson were worth $14,194,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of JNJ. Christopher J. Hasenberg Inc acquired a new stake in shares of Johnson & Johnson in the 1st quarter worth $31,000. Keener Financial Planning LLC purchased a new stake in Johnson & Johnson in the fourth quarter valued at about $40,000. WFA Asset Management Corp boosted its holdings in Johnson & Johnson by 61.4% in the fourth quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock worth $40,000 after acquiring an additional 97 shares in the last quarter. Vermillion & White Wealth Management Group LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at about $44,000. Finally, Disciplined Equity Management Inc. purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at approximately $45,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on JNJ shares. The Goldman Sachs Group dropped their target price on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research report on Friday, July 19th. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and upped their target price for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. TD Securities dropped their price target on Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. StockNews.com cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 8th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a research report on Tuesday, July 30th. Seven analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $173.21.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ traded up $0.09 during midday trading on Wednesday, reaching $158.48. 4,882,529 shares of the stock were exchanged, compared to its average volume of 7,355,267. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The firm has a market cap of $381.41 billion, a price-to-earnings ratio of 9.89, a PEG ratio of 2.63 and a beta of 0.52. The firm has a 50-day simple moving average of $151.63 and a two-hundred day simple moving average of $153.06. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $175.39.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating the consensus estimate of $2.71 by $0.11. The company had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. Johnson & Johnson’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same period last year, the company earned $2.80 earnings per share. As a group, analysts anticipate that Johnson & Johnson will post 10.07 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, August 27th. This represents a $4.96 annualized dividend and a yield of 3.13%. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.